← Back to list
Laboratoires Expanscience
Main severance
Details not public
Health cover
Statutory portability
Status
In negotiation
Positions affected
119 positions / 724 headcount (~16%)
Context
Why the plan was launched and who is affected
Plan type
Sector crisis
Sites affected
France sites — Courbevoie (HQ) + cosmetics production (Mustela)
Rationale & context
Preventive PSE announced summer 2025 at Expanscience facing HAS delisting threat for Piasclédine, the lab's flagship drug (arthritis). If HAS effectively delists, the economic impact on the family SME would be major (Piasclédine represents a substantial share of pharma group revenue). 119 cuts of 724 headcount = 16% — close to critical threshold for an SME. Model case of PSE triggered by anticipation of a regulatory decision.
Look here first
Severance
What employees received — legal base, supra-legal, caps
Legal / collective indemnity
This is the minimum guaranteed by your sector's collective agreement. Paid to every affected employee on top of the statutory legal indemnity.
Pharmaceutical Industry collective indemnity (IDCC 176)
Underlying formula · Managers: scale by category with seniority bonus. Non-managers: generally legal minimum.
Supra-legal top-up
The amount negotiated by unions ON TOP OF the legal and collective minimum. Often the largest part of the package.
Information not public
Notice period
Period between the dismissal notification and the actual departure. The employee remains paid during this time, whether they work or not.
Not specified in the PSE.
Collective minimum · Pharmaceutical industry agreement (IDCC 176) — Managers: 3 months (art. 25). Non-managers: 1 to 2 months by seniority.
Example — rough estimate
For a manager (cadre) employee with 5 years of seniority and €3,500 gross/month:
| Collective severance | (1.5 months × €3,500) | €5,250 |
| Supra-legal severance | — | Not publicly disclosed |
Very rough illustrative estimate. Your actual amount depends on your exact reference salary (max of 1/12 of last 12 months or 1/3 of last 3 months, bonuses included — art. R1234-4 French Labour Code), your precise status (manager/non-manager/ETAM), your hire date and your individual situation. For a personalized calculation of the legal indemnity, use the official French Ministry of Labour simulator.
Notes & sources
Additional information and references
Notes
PSE announced summer 2025 at Laboratoires Expanscience (French family group — Mustela, Piasclédine). 119 positions of 724 (16%). Main rationale: fear of Piasclédine delisting (flagship arthritis drug, threatened by HAS for several years). Representative case of a 'preventive' PSE facing an anticipated regulatory decision.
Support
Outplacement, training, retraining aid and mobility
No one has documented this point for this plan yet. If you've been through it or have the document, your help will make this file useful to the next person.
Selection
How departures are decided — criteria and voluntary scheme
No one has documented this point for this plan yet. If you've been through it or have the document, your help will make this file useful to the next person.
📄 FCE-CFDT — Gros temps sur la pharmacie (été 2025) · View source →